史录文/管晓东团队在中国抗肿瘤药物创新性与临床获益评价中取得进展

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (2): 156-157.

史录文/管晓东团队在中国抗肿瘤药物创新性与临床获益评价中取得进展

北京大学药学院

北京大学药学院

收稿日期:2023-02-15 修回日期:2023-02-16 接受日期:2023-02-16 出版日期:2023-02-28 发布日期:2023-03-06

The team of Prof. Luwen Shi and Prof. Xiaodong Guan has made progress in the innovation and clinical benefit evaluation of cancer drugs in China

School of Pharmaceutical Sciences, Peking University Health Science Center

School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2023-02-15 Revised:2023-02-16 Accepted:2023-02-16 Online:2023-02-28 Published:2023-03-06

摘要/Abstract

摘要：

2023年1月16日, 北京大学药学院药事管理与临床药学系史录文/管晓东团队在肿瘤学权威期刊自然·综述系列Nature Reviews Clinical Oncology 在线发表了题为“Newly approved cancer drugs in China — innovation and clinical benefit”的评论文章。该文从作用机制、治疗需求与临床获益三个维度系统评价了2005-2021年在中国获批上市的抗肿瘤新药的创新性及临床价值。

Supporting:

北京大学药学院. 史录文/管晓东团队在中国抗肿瘤药物创新性与临床获益评价中取得进展[J]. 中国药学(英文版), 2023, 32(2): 156-157.

School of Pharmaceutical Sciences, Peking University Health Science Center. The team of Prof. Luwen Shi and Prof. Xiaodong Guan has made progress in the innovation and clinical benefit evaluation of cancer drugs in China[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(2): 156-157.